Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, with a year-to-date increase of 0.1%, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, positioning it as a key pillar for economic growth and industrial upgrading, particularly highlighting the innovative drug sector as a core beneficiary [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, elevating the field to a national industrial support framework, which is expected to enhance market focus on related technologies [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, with potential payments totaling up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has reached a global exclusive licensing agreement with UCB for ATG-201, with an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a targeted therapy for non-small cell lung cancer [14] - Yahui Pharmaceutical has obtained approval for APL-1702, a product aimed at treating cervical intraepithelial neoplasia [15] Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]

Group 1 - The People's Bank of China will implement a moderately loose monetary policy this year, utilizing various tools such as reserve requirement ratio cuts and interest rate reductions to ensure ample market liquidity and align social financing scale with economic growth and price level expectations [3] - The China Securities Regulatory Commission (CSRC) will introduce two new measures: deepening the reform of the ChiNext board with more inclusive listing standards and optimizing the refinancing mechanism to enhance efficiency for high-quality listed companies [4][11] - The global energy market has been severely impacted by the near "standstill" of commercial transportation in the Strait of Hormuz, with significant price increases in oil and natural gas [5][7] Group 2 - The National Development and Reform Commission (NDRC) expects this year's GDP increment to exceed 6 trillion yuan, supporting employment stability and risk prevention [8] - The Ministry of Finance announced a more proactive fiscal policy, with total expenditures exceeding 30 trillion yuan and new government bond issuance reaching a record high of 11.89 trillion yuan [9] - The CSRC has released new regulations on short-term trading, effective from April 7, 2026, to enhance market stability [12] Group 3 - The A-share market showed a mixed performance, with major indices experiencing fluctuations, while the Hong Kong stock market rebounded strongly [13][14] - The development of REITs in China is seen as a golden opportunity, with strong interest from various enterprises [14] - The CSRC is focusing on enhancing the stability and vitality of the capital market through various reforms and support measures [11][12]

证券代码：688176 证券简称：亚虹医药 公告编号：2026-008 江苏亚虹医药科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、股票交易异常波动的具体情况 1 江苏亚虹医药科技股份有限公司（以下简称"公司"）股票交易于 2026 年 3 月 4 日、3 月 5 日和 3 月 6 日连续 3 个交易日收盘价格涨幅偏 离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交 易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易 异常波动的情形。 经公司自查并发函征询公司控股股东、实际控制人，截至本公告披露 日，公司不存在应披露而未披露的重大事项。 医药产品具有高科技、高风险、高附加值的特点，药品的前期研发以 及产品从研制、临床试验报批到投产的周期长，临床试验进度及结果、 未来产品市场竞争形势均存在一定的不确定性。药品获得上市批准后 的生产和商业化将受到政策环境、市场需求及市场竞争等多种因素的 影响，存在一定的不确定性，敬请广大投资者谨慎决策，注意防 ...

Market Overview - A-shares rose again on March 6, with over 4,200 stocks in the green; Hong Kong stocks surged, with the Hang Seng Index up nearly 2% and the Hang Seng Tech Index up nearly 4% [1] - The Shanghai Composite Index closed up 0.38% at 4,124.19 points, the Shenzhen Component Index rose 0.59%, the ChiNext Index increased by 0.38%, and the Sci-Tech Innovation Board Index gained 0.87% [1] - Total trading volume in the Shanghai and Shenzhen markets was approximately 2.22 trillion yuan, a decrease of over 190 billion yuan from the previous day [1] Electric Equipment Sector - The electric equipment sector showed strong performance, with Zhongyi Technology rising nearly 15%, Nanfang Technology and Ankao Zhidian up over 10%, and Shun Sodium Co. achieving a three-day winning streak [3] - China West Electric continued to set historical highs with an increase of over 6% [3] Pharmaceutical Sector - The pharmaceutical sector saw significant gains, particularly in innovative drugs and weight-loss drug concepts, with Yahu Pharmaceutical hitting a 20% limit up and Rongchang Bio rising nearly 14% [7] - Other notable performers included Shanghai Yizhong and Bai'ao Saitou, both up over 9%, and Junshi Biosciences, which rose nearly 5% [7] Agricultural Sector - The agricultural sector collectively rose, with Yasheng Group and Dunhuang Seed Industry hitting the limit up, while COFCO Technology and Xiangjia Co. increased by over 7% [11] - Muyuan Foods and other stocks in the sector rose over 5% [11] Policy Insights - The 2026 government work report emphasizes the cultivation of emerging industries, including biomedicine, and encourages state-owned enterprises to lead in application scenarios [9] - The report highlights the importance of the biopharmaceutical industry, indicating strong policy support and confidence in the sector's growth potential [9] - The report also outlines plans for enhancing grain production capacity and agricultural technology, suggesting a focus on agricultural innovation and seed technology [13]

Market Overview - A-shares and Hong Kong stocks showed a collective strength today, with A-shares opening lower but rising throughout the morning session [1][2] - The Shanghai Composite Index rose by 0.25%, the Shenzhen Component increased by 0.8%, the ChiNext Index gained 0.85%, and the Sci-Tech Innovation Index climbed 1.29% [4] Sector Performance - The pharmaceutical and biotechnology sector experienced a significant surge, with the sector rising over 2% and multiple stocks hitting the daily limit [5] - The agricultural sector also performed well, with gains exceeding 3%, highlighted by stocks like Xiangjia Co. and Dunhuang Seed Industry reaching their daily limits [5] - Other sectors such as environmental protection, basic chemicals, construction decoration, social services, and military industry also saw notable increases [7] Notable Stocks - Key stocks in the pharmaceutical sector included: - Yahui Pharmaceutical-U (688176) with a price of 16.78, up 20.03% [6] - Huakang Clean (301235) at 56.43, up 11.94% [6] - International Medicine (000516) at 5.01, up 10.11% [6] - The virtual power plant concept stocks performed strongly, with the index surging over 3% and several stocks hitting their daily limits [9] New Listings - The newly listed stock, Gude Electric Materials, saw its price increase by over 150% during trading. The company specializes in thermal runaway protection components for electric vehicle batteries and high-performance insulation products for electrical applications [12] Hong Kong Market - The Hong Kong market also showed positive momentum, with the Hang Seng Index rising nearly 2% and the Hang Seng Technology Index increasing by over 3% [14] - Major stocks in the Hang Seng Technology Index, such as JD.com, Trip.com, and NetEase, saw price increases exceeding 5% [16]

Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [8]. Core Insights - The pharmaceutical sector experienced a decline of 2.67% on March 3, 2025, underperforming the CSI 300 index by 1.13 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [4]. - Notable performances within sub-industries included offline pharmacies (-0.62%), blood products (-1.37%), and in vitro diagnostics (-1.50%), while hospitals (-4.32%), medical R&D outsourcing (-3.53%), and other biological products (-3.39%) lagged behind [4]. - Key individual stock performances included Kanghui Co., Ltd. (+10.01%), Lianhuan Pharmaceutical (+3.89%), and Jiuan Medical (+3.42%) on the gainers' list, while Tianzhihang (-11.45%), Saike Xide (-11.06%), and Wanze Co., Ltd. (-10.01%) were among the biggest losers [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3]. Industry News - Eli Lilly's Lebrikizumab, an anti-IL-13 monoclonal antibody, has received acceptance for market application in China, having previously been approved by the FDA in the U.S. for moderate to severe atopic dermatitis [5]. - Yihong Pharmaceutical's APL-1702 has been approved for the treatment of confirmed CIN2 patients aged 18 and above [5]. - Baiyao's Usymro has received approval from the UK Medicines and Healthcare products Regulatory Agency, enhancing the company's international presence [5]. - Yiling Pharmaceutical's chemical raw material drug, Pomalidomide, has been approved for market application [6]. - Haichuang Pharmaceutical's HP515, a selective THR-β agonist for treating metabolic-associated fatty liver disease, has completed participant enrollment in its Phase IIa clinical trial [6].

证券代码：688176 证券简称：亚虹医药 公告编号：2026-007 江苏亚虹医药科技股份有限公司 自愿披露关于希维她®获得国家药品监督管理局批准 上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的《药品注册证书》，批准公司APL-1702（商标名：希维她®/CEVIRA®， 通用名：盐酸氨酮戊酸己酯软膏宫颈光动力治疗系统）上市，用于治疗 18 岁及 以上经组织学证实为子宫颈上皮内瘤变 2 级（CIN2）患者，排除子宫颈浸润癌 和子宫颈原位腺癌。根据公开资料查询，希维她®作为一款集药物和器械为一体 的光动力产品，是全球首个针对该患者人群获批上市的非手术的无创治疗产品。 希维她®在治疗上具有精准靶向清除病变、HPV（人乳头瘤病毒）免疫清除、 生育功能保护的独特优势，尤其是其无创治疗特质，可最大程度保全宫颈解剖结 构和生理功能完整，使近 60%患者延缓或避免手术，为适宜女性提供有效控制病 变、保留生育功能的更优选 ...

Core Viewpoint - Jiangsu Yahuang Pharmaceutical Technology Co., Ltd. has successfully obtained acceptance from the European Medicines Agency (EMA) for its product APL-1702 (CEVIRA), intended for the treatment of high-grade squamous intraepithelial lesions (HSIL) [2][3] Product Information - APL-1702 is a pioneering photodynamic therapy product, combining a medicated ointment with a disposable cervical photodynamic treatment lamp, designed for outpatient use with a treatment time of under 10 minutes [3] - The innovative cold light source technology used in APL-1702 maintains tissue temperature below 42°C, resulting in 97% of patients reporting no pain during treatment, thus enhancing comfort and reducing the risk of tissue damage [3] - The application for market approval is based on international multi-center Phase III clinical trials, which included over 20% European patients, with results to be published in the journal "Med" and presented at several international conferences in 2024 [3] Financial Performance - For the fiscal year 2025, the company reported a revenue of 277.12 million yuan, primarily from the sales of Pazopanib tablets and Nilotinib tablets, marking a 37.49% increase compared to the previous year [10] - The net loss attributable to shareholders was 419.34 million yuan, with a significant increase in losses due to ongoing high R&D investments and the transition to a commercialized system [10] - Total assets at the end of the reporting period were 2.057 billion yuan, a decrease of 7.45% year-on-year, while equity attributable to shareholders decreased by 19.87% [10] Clinical Development Progress - APL-1702's Phase III clinical trial results were presented at the International Photodynamic Association conference and published in "Med" [7] - The company has also received approval for the Phase I clinical trial of APL-2401 for advanced solid tumors, which was expedited under new regulatory policies [8] - A portable blue light bladder endoscope, APLD-2304, has had its registration application accepted by the EU, aimed at improving bladder cancer detection rates [8]

证券日报网讯 2月27日，亚虹医药发布公告称，公司2025年实现营业总收入27712.15万元，同比增长 37.49%；归属于母公司所有者的净利润为-41934.08万元，亏损较上年同期扩大。 （文章来源：证券日报） ...

证券代码：688176 证券简称：亚虹医药 公告编号：2026-006 江苏亚虹医药科技股份有限公司 自愿披露关于 APL-1702 上市许可申请成功获得欧洲药 品管理局受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、江苏亚虹医药科技股份有限公司（以下简称"公司"）近日收到欧洲药品 管理局（以下简称"EMA"）的通知，公司产品 APL-1702（CEVIRA）拟用于治 疗宫颈高级别鳞状上皮内病变（HSIL）患者的上市许可申请已获得 EMA 受理。 2、上市许可申请获得受理后，产品仍需通过后续审评审批环节，能否成功 上市及具体上市时间存在不确定性。即使在获批后，其最终能否实现商业目标亦 存在一定的不确定性。上述产品上市许可申请获得受理事项，对公司近期业绩不 会产生重大影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将严格按 照有关规定对项目后续进展及时履行信息披露义务。 一、产品情况 APL-1702 是一款全球首创、中国首发的光动力治疗产品，由盐酸氨酮戊酸 己酯软膏和一次性使用宫颈光动力 ...